Core Insights - Intellia Therapeutics has been a leader in the CRISPR medicine space since its inception in 2014, focusing on in vivo treatment of genetic diseases [1] - The company is on the verge of completing trials that will lead to the approval of some of the first in vivo CRISPR therapeutics [1] Clinical Trials - Intellia is currently conducting 3 Phase III trials [2] - The company has enrolled over 600 total patients, contributing to a substantial safety database [2] - Patients have been followed for over 4 years, providing extensive data on long-term safety [2] - The company has published 5 landmark publications related to its research [2]

Intellia Therapeutics (NasdaqGM:NTLA) FY Conference January 14, 2026 12:00 PM ET Company ParticipantsEd Dulac - CFOJohn Leonard - CEOConference Call ParticipantsNone - Analyst 1Brian Cheng - Senior Biotech AnalystNone - Analyst 2Brian ChengGood morning. Thanks for joining us for another session at the 44th JPMorgan Healthcare Conference. I'm Brian Cheng, one of the senior biotech analysts here at the firm. On stage, we have Intellia Therapeutics. I'll now pass the mic to their CEO, John Leonard, for a short ...